Trial Profile
A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2 Dose Regimens of TP-434 Compared with Ertapenem in Adult Community- Acquired Complicated Intra-abdominal Infections
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2022
Price :
$35
*
At a glance
- Drugs Eravacycline (Primary) ; Ertapenem
- Indications Gram-negative infections; Intra-abdominal infections
- Focus Therapeutic Use
- Sponsors Tetraphase Pharmaceuticals
- 19 Sep 2018 According to Tetraphase Pharmaceuticals media release, data from this trial will be presented at the Infectious Disease Society of Americas (IDSA) Infectious Disease Week (IDWeek) 2018.
- 16 Dec 2013 Results published in the Antimicrobial Agents and Chemotherapy.
- 04 Sep 2013 Results will be presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2013) according to a Trius Therapeutics media release.